Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Personalis Inc

04X
Current price
4.56 EUR -0.49 EUR (-9.75%)
Last closed 5.58 USD
ISIN US71535D1063
Sector Healthcare
Industry Diagnostics & Research
Exchange Frankfurt Exchange
Capitalization 335 611 200 USD
Yield for 12 month +269.23 %
1Y
3Y
5Y
10Y
15Y
04X
21.11.2021 - 28.11.2021

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California. Address: 6600 Dumbarton Circle, Fremont, CA, United States, 94555

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

7.05 USD

P/E ratio

Dividend Yield

Current Year

+73 481 000 USD

Last Year

+65 047 000 USD

Current Quarter

+22 580 000 USD

Last Quarter

+19 525 000 USD

Current Year

+18 208 000 USD

Last Year

+13 350 000 USD

Current Quarter

+8 037 000 USD

Last Quarter

+5 493 000 USD

Key Figures 04X

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -69 627 000 USD
Operating Margin TTM -74.81 %
PE Ratio
Return On Assets TTM -23.28 %
PEG Ratio
Return On Equity TTM -56.49 %
Wall Street Target Price 7.05 USD
Revenue TTM 80 027 000 USD
Book Value 2.12 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 35.2 %
Dividend Yield
Gross Profit TTM 13 350 000 USD
Earnings per share -1.64 USD
Diluted Eps TTM -1.64 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -101.78 %

Dividend Analytics 04X

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History 04X

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation 04X

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 3.69
Price Sales TTM 4.1937
Enterprise Value EBITDA -0.0283
Price Book MRQ 2.9893

Financials 04X

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 04X

For 52 weeks

0.89 USD 7.2 USD
50 Day MA 5.21 USD
Shares Short Prior Month 2 937 685
200 Day MA 2.7 USD
Short Ratio 4.44
Shares Short 3 118 660
Short Percent 7.52 %